Veracyte, Inc. VCYT

VCYT Company Overview

Veracyte, Inc. is a U.S.-based diagnostics and life sciences company focused on advanced genomic testing and cancer diagnostics. The company develops and commercializes molecular diagnostic tests intended to improve the accuracy of disease diagnosis, reduce unnecessary procedures, and support personalized treatment decisions. Veracyte primarily operates within the molecular diagnostics, genomic medicine, and precision oncology industries, serving physicians, hospitals, pathology laboratories, biopharmaceutical companies, and patients. Its revenue is primarily generated through diagnostic testing services, genomic classifier products, and collaborations with pharmaceutical and research organizations.

The company is best known for its genomic classifiers used in thyroid, lung, breast, prostate, and bladder cancer assessment, including products such as the Afirma and Decipher platforms. Veracyte has positioned itself as a provider of integrated genomic solutions that combine sequencing technologies, machine learning-driven analytics, and decentralized testing capabilities. Founded in 2006 and headquartered in South San Francisco, California, Veracyte expanded from a thyroid-focused diagnostics company into a broader oncology and pathology enterprise through internal development and acquisitions, including the acquisition of Decipher Biosciences and HalioDx.